Patents Assigned to Ultimovacs AS
  • Telomerase polypeptide vaccine for treating cancer
    Patent number: 11529403
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: December 20, 2022
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
    Patent number: 11419927
    Abstract: A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: August 23, 2022
    Assignee: Ultimovacs AS
    Inventors: Gustav Gaudernack, Audun Tornes
  • Telomerase polypeptide vaccine for treating cancer
    Patent number: 10383928
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: August 20, 2019
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Telomerase polypeptide vaccine for treating cancer
    Patent number: 9657068
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: May 23, 2017
    Assignee: Ultimovacs AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso